Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Oriel Therapeutics

2001 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$330M LATEST DEAL AMOUNT
Description

Developer of inhaled drug delivery systems for asthma and COPD medicines. The company offers products for the treatment of asthma and COPD.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Acquirer
Primary Office
  • 630 Davis Drive
  • Suite 120
  • Durham, NC 27713
  • United States

+1 (919) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Oriel Therapeutics’s full profile, request a free trial.

Oriel Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Apr-2010 $330M 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 24-Sep-2008 000.00 000.00 Completed Generating Revenue
4. Grant 00000 000 Completed
3. Corporate 000 000 Completed
2. Early Stage VC (Series B) Completed
1. Early Stage VC (Series A) Completed
To view this company’s complete deal history including valuation and funding, request access »

Oriel Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
HealthCare Ventures Venture Capital Minority 000 0000 000000 0
Insight Accelerator Labs Accelerator/Incubator Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
New Leaf Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Oriel Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Richard Fuller Ph.D Chief Executive Officer

3 Former Executives

You’re viewing 1 of 4 executives. Get the full list »